Brain Tumor - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 114

Brain Tumor – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Brain Tumor - Pipeline Review, H2 2012', provides an overview of the Brain Tumor therapeutic pipeline. This report provides information on the therapeutic development for Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Tumor. 'Brain Tumor - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Tumor.
- A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Brain Tumor pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Brain Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Brain Tumor pipeline depth and focus of Brain Tumor therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Brain Tumor Therapeutic Products under Development, Key Players in Brain Tumor Therapeutics, Brain Tumor Pipeline Overview, Brain Tumor Pipeline, Brain Tumor Pipeline Assessment

2
List of Tables 8
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Brain Tumor Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Brain Tumor 11
Brain Tumor Therapeutics under Development by Companies 13
Brain Tumor Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Brain Tumor Therapeutics – Products under Development by Companies 21
Brain Tumor Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Brain Tumor Therapeutics Development 24
Genzyme Corporation 24
YM BioSciences Inc. 25
Avanti Therapeutics 26
Hutchison MediPharma Limited 27
Discovery Genomics, Inc. 28
Celtic Pharmaceutical Holdings L.P. 29
Brain Tumor – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
HMPL-813 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Everolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MR1-1KDEL. - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Xerecept - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MLN-518 + Bevacizumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Temozolomide + Etoposide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Avastin + XRT + Temozolomide + Irinotecan - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NHERF-1 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Dendritic Cell Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Gleevec - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ZD1839 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Ritonavir + Lopinavir - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Temozolomide + Radiation Therapy - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Topotecan - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Valproic acid + Temodar + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Biomab EGFR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
O6-Benzylguanine + Temozolomide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Verteporfin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MLN8237 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Dendritic cells + Imiquimod - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Mozobil - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Filgrastim + Pegfilgrastim + Carboplatin + Cisplatin + Dexamethasone + Etoposide + Ifosfamide + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 65
Temsirolimus + Valproic Acid - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CT-2103 + Temozolomide + Radiation Therapy - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Carboplatin + Vincristine + Temozolomide + G-CSF + Thiotepa + Etoposide + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 69
XR9576 + Filgrastim + Docetaxel + Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
Temozolomide + Etoposide + Trofosfamid - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Tamoxifen + Carboplatin + Topotecan - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
GW786034 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Sorafenib + Temozolomide - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cytovene - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Lapatinib Ditosylate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PF02341066 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
BCNU + CACP + Radiation Therapy - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Montanide ISA-51 + SVN53-67/M57-KLH + GM-CSF - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Satraplatin - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Imetelstat Sodium - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cytoxan + Melphalan + Autologous Stem Cell Transplantation - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Carboplatinum + VP-16 + Thiotepa + Autologous Stem Cell Transplantation - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Autologous Tumor Lysate-Pulsed DC Vaccine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Temozolomide + Temsirolimus - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Sorafenib + Radiation Therapy - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Panobinostat + Radiation Therapy - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Topotecan - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Topotecan + Thiotepa + Carboplatin + Melphalan + Etoposide + Stem Cell Transplantation - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 96
CT-BT-316 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Brain Tumor Therapeutics – Drug Profile Updates 98
Brain Tumor Therapeutics – Discontinued Products 102
Brain Tumor Therapeutics - Dormant Products 103
Brain Tumor – Product Development Milestones 105
Featured News & Press Releases 105
Jun 27, 2012: Celtic Pharma Announces Presention Of Phase I/II Study Results Of Xerecept At International Symposium For Pediatric Neuro-Oncology 105
May 22, 2012: Celtic Pharma Successfully Completes Phase I/II Study Of Xerecept In Pediatric Patients With Cerebral Tumors 106
Oct 03, 2011: Celtic Pharma Completes Enrollment In Dose Tolerance Trial Evaluating Xerecept In Pediatric Patients With Primary And Metastatic Brain Tumors 107
Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 108
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 108
Feb 02, 2011: Antisense Pharma Receives Approval For Clinical Studies In South Korea And Taiwan In Malignant Brain Tumors 109
Nov 02, 2010: Antisense Pharma’s Trabedersen In Malignant Brain Tumors: Phase IIb Data Published In Neuro-Oncology 110
Oct 29, 2010: Novartis Drug Afinitor Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis. 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Tables
Number of Products Under Development for Brain Tumor, H2 2012 11
Products under Development for Brain Tumor – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Genzyme Corporation, H2 2012 24
YM BioSciences Inc., H2 2012 25
Avanti Therapeutics, H2 2012 26
Hutchison MediPharma Limited, H2 2012 27
Discovery Genomics, Inc., H2 2012 28
Celtic Pharmaceutical Holdings L.P., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Brain Tumor Therapeutics – Drug Profile Updates 98
Brain Tumor Therapeutics – Discontinued Products 102
Brain Tumor Therapeutics – Dormant Products 103

List of Figures
Number of Products under Development for Brain Tumor, H2 2012 11
Products under Development for Brain Tumor – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Customers who bought this item also bought

• Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Brain Tumor – Pipeline Review, H1 2013
• Nausea - Pipeline Review, H2 2012
• Astrocytoma - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Primary Systemic Amyloidosis - Pipeline Review, H2 2012
• Allergic Asthma - Pipeline Review, H2 2012
• Neurofibromatoses - Pipeline Review, H2 2012
• Brain Metastasis - Pipeline Review, H2 2012